Multiple sclerosis itself is rarely listed as the immediate cause on a death certificate, but the disease shortens life by about seven years on average and sets in motion a chain of complications that can become fatal. A large population-based study in Wales found a median life expectancy of roughly 75 years for people with MS, compared with about 82 years in the general population, with an overall mortality rate nearly three times higher than expected.1PubMed. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study The fatal complications fall into a handful of categories, and understanding them is genuinely useful for people with MS and their families, because many are preventable or at least manageable if caught early.
The Gap Between MS and the General Population
For the first couple of decades after diagnosis, survival in MS looks surprisingly close to the general population. A large French observational study found that the survival curves only begin to diverge meaningfully after about 20 years of disease, at which point the gap widens to roughly seven years of lost life expectancy.2PubMed Central. Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study That delayed divergence matters. It means the danger is not an early sudden death for most people. It is a slow accumulation of disability over decades, with the complications of that disability becoming increasingly life-threatening in later stages.
Age at diagnosis also shapes the picture. A Finnish register study found that people diagnosed before age 30 had a 15-year mortality rate nearly five times higher than expected for their age group, while those diagnosed after 50 had about twice the expected mortality.3PubMed Central. Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register study That sounds counterintuitive, but younger people normally have very low death rates, so even a modest absolute increase from MS translates into a high relative risk. The absolute risk of dying in any given year is still higher for someone diagnosed at 55 than at 25, but the disease punches above its weight relative to what is expected for a younger person.
Respiratory Failure
If there is one complication that most directly bridges MS to death, it is respiratory failure. The disease damages the brainstem and spinal cord through demyelinating lesions, and these areas control the muscles you breathe with. When lesions hit the right spots, the diaphragm weakens, the chest wall muscles lose coordination, and the cough reflex dulls. You cannot clear your airways as effectively, and your lungs become sitting targets for infection.
Acute respiratory failure from MS is uncommon, but when it happens, it is typically caused by new demyelinating plaques in the brainstem or upper spinal cord.4PubMed. Respiratory dysfunction in multiple sclerosis Chronic respiratory muscle weakness is a more typical pattern. A study of MS patients with respiratory involvement found that diaphragm weakness was a major factor in many cases, with others affected by bulbar weakness or impaired automatic breathing control.5PubMed. Respiratory involvement in multiple sclerosis Some patients develop sleep apnea or abnormal breathing patterns (like breathing that gets stuck in the “inhale” phase) without realizing there is a problem until they become seriously ill.
The practical consequence is that a respiratory infection that a healthy person would fight off in a week can land someone with advanced MS in the hospital on a ventilator. Pneumonia, in particular, is one of the leading causes of death in MS. A U.S. population-based mortality study found that when MS was mentioned on a death certificate, respiratory infection was about three times more likely to be listed as a contributing cause compared to matched deaths without MS.6PubMed Central. Multiple cause of death analysis in multiple sclerosis: A population-based study
Aspiration Pneumonia and Swallowing Problems
Swallowing is one of those abilities most people never think about until it fails. It requires precise coordination between the tongue, throat muscles, and the epiglottis (the flap that seals off your airway when you swallow). MS can disrupt this process by damaging the brainstem areas that coordinate swallowing, the cerebellum that fine-tunes the muscle timing, and the nerves that control the tongue and face.7Frontiers in Neurology. Dysphagia in multiple sclerosis: pathophysiology, assessment, and management—an overview The result is called dysphagia, and it means food, liquid, or saliva can slip into the lungs instead of the stomach.
When that happens repeatedly, the lungs become inflamed and infected, a condition called aspiration pneumonia. This is distinct from the “community-acquired” pneumonia most people think of. It tends to be harder to treat because it involves bacteria from the mouth and throat that are especially destructive in lung tissue. The same population-based mortality study found that aspiration pneumonia was seven times more likely to appear as a contributing cause of death when MS was present.6PubMed Central. Multiple cause of death analysis in multiple sclerosis: A population-based study That makes it one of the single largest contributors to MS-related death, and it is worth emphasizing that swallowing problems can appear even in people with relatively mild disability, if the lesions happen to land in strategically important brainstem areas.7Frontiers in Neurology. Dysphagia in multiple sclerosis: pathophysiology, assessment, and management—an overview
Infections Beyond the Lungs
Pneumonia gets the most attention, but infections at other sites also pose serious risks. Bladder dysfunction is extremely common in MS, and the combination of incomplete bladder emptying, catheter use, and impaired mobility creates fertile ground for urinary tract infections.8PubMed Central. Urinary tract infections in multiple sclerosis: under-diagnosed and under-treated? A clinical audit at a large University Hospital Most UTIs are annoying but treatable. In advanced MS, though, they can escalate to kidney infection and then to sepsis, a body-wide inflammatory response to infection that can be fatal. The population-based mortality analysis found that UTIs were about ten times more likely to contribute to death when MS was mentioned on the death certificate, with the risk especially pronounced in men.6PubMed Central. Multiple cause of death analysis in multiple sclerosis: A population-based study
Skin infections tied to pressure ulcers are another overlooked pathway. People who spend most of their time in a wheelchair or bed develop sores from sustained pressure on bony areas like the tailbone and heels. These sores can become deep, infected wounds. MS was one of the conditions most strongly associated with pressure ulcer deaths in a U.S. mortality study, and sepsis was reported in about 40% of those deaths.9PubMed. Pressure ulcers: more lethal than we thought? Skin disease broadly was about five times more likely to appear on death certificates when MS was present.6PubMed Central. Multiple cause of death analysis in multiple sclerosis: A population-based study
Blood Clots
Immobility is the connective tissue (so to speak) between MS and many of its fatal complications, and blood clots are a prime example. When you stop moving your legs regularly, blood pools and can form clots in the deep veins, a condition called deep vein thrombosis. The real danger is when a piece of clot breaks off and travels to the lungs, causing a pulmonary embolism that can be immediately fatal.
A large population-based cohort study found that people with MS had roughly three times the risk of deep vein thrombosis and nearly three times the risk of pulmonary embolism in the first year after diagnosis, compared to matched controls. That risk stayed elevated over decades of follow-up.10PubMed. Multiple sclerosis and risk of venous thromboembolism: a population-based cohort study Among MS patients who were bedridden or wheelchair-bound, one prospective study found deep vein thrombosis in over 40% of participants, many of whom had chronic leg swelling as a warning sign that was going unrecognized.11PubMed. Risk of deep venous thrombosis (DVT) in bedridden or wheelchair-bound multiple sclerosis patients: a prospective study That number is striking, and it suggests this risk is chronically under-screened in people with advanced MS.
Heart Problems From Autonomic Damage
MS can affect the heart in ways that are easy to miss. The autonomic nervous system, which regulates heart rate, blood pressure, and other involuntary functions, runs through the brainstem and spinal cord. Lesions in these areas can disrupt its signaling. About two-thirds of people with MS show some degree of cardiovascular autonomic dysfunction on testing, and roughly half have orthostatic hypotension, where blood pressure drops sharply upon standing.12Annals of Clinical Neurophysiology. Autonomic dysfunction in multiple sclerosis and neuromyelitis optica spectrum disorder
Most of the time, this causes nuisance symptoms like dizziness or fatigue. But brainstem lesions can also trigger heart rhythm abnormalities such as atrial fibrillation, especially during relapses. In rare cases, the acute stress of a relapse can even cause a form of stress-induced heart damage. Elevated stress hormones from active brain lesions can injure heart muscle cells and disrupt the heart’s electrical conduction system.12Annals of Clinical Neurophysiology. Autonomic dysfunction in multiple sclerosis and neuromyelitis optica spectrum disorder A systematic review concluded that cardiac autonomic dysfunction in MS can trigger serious cardiovascular complications that reduce life expectancy.13PubMed Central. Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of Immunotherapies
Beyond the autonomic pathway, people with MS also face a higher risk of conventional cardiovascular events. An English population study found that MS was associated with about a 30% increase in the risk of acute coronary syndrome, a 60% increase in stroke risk, and roughly 50% higher cardiovascular mortality compared to matched controls.14JAMA Neurology. Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England Whether MS directly accelerates atherosclerosis or whether it is the reduced activity, medication side effects, and chronic inflammation that drive this remains debated, but the increased risk is consistent across studies.
Suicide
This is a difficult topic, but it would be dishonest to leave it out. Depression is extremely common in MS, driven by a combination of the psychological burden of a progressive disease and the biological effects of brain lesions and immune system changes on mood-regulating circuits. The suicide risk in people with MS is roughly double that of the general population.15PubMed Central. Depression and Suicidality in Multiple Sclerosis: Red Flags, Management Strategies, and Ethical Considerations
A systematic review identified several risk factors for suicide in MS: severity of depression, social isolation, younger age, a progressive (rather than relapsing) disease subtype, higher physical disability, and earlier disease course.16PubMed. Suicide risk in multiple sclerosis: a systematic review of current literature That last one is worth pausing on. People newly diagnosed and still coming to terms with the disease may be at particular risk, even before physical disability is severe. Depression in MS also correlates with poorer treatment adherence and lower quality of life, creating a feedback loop where untreated depression accelerates the overall decline.17PubMed Central. Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art Screening for depression and providing mental health support is not a nice-to-have; it is a survival issue.
When MS Itself Kills Quickly
Everything discussed so far describes the typical, slow-moving trajectory of MS. But there is a rare and terrifying variant called Marburg disease (or Marburg variant MS), a fulminant form characterized by rapid, catastrophic neurological decline that can lead to death within weeks to months of onset.18PubMed Central. A Patient with Marburg’s Variant of Multiple Sclerosis Responded Well to Cyclophosphamide Unlike typical MS, which waxes and wanes over years, Marburg variant involves massive, widespread demyelination in a single aggressive episode. There are no established treatment guidelines, and many reported cases have ended in death within a year.19PubMed. The most fulminant course of the Marburg variant of multiple sclerosis-autopsy findings
Marburg variant is genuinely rare, and most neurologists will see very few cases in a career. Aggressive immunosuppressive treatment has shown promise in individual cases, but the evidence is limited to case reports rather than clinical trials.20Frontiers in Immunology. Case Report: Marburg variant of multiple sclerosis and review of its complicated treatment If you or someone you know has typical relapsing-remitting or even primary progressive MS, Marburg variant is not what is happening and not what to worry about. But it is worth knowing it exists, because it occasionally makes headlines and can cause unnecessary panic.
Risks From MS Treatments Themselves
One of the more unsettling realities of MS management is that some of the most effective treatments carry their own rare but serious risks. The most notable example involves natalizumab, a highly effective drug for relapsing MS. In a small number of patients, natalizumab suppresses immune surveillance in the brain enough to allow the JC virus, which most people carry harmlessly, to cause a devastating brain infection called progressive multifocal leukoencephalopathy (PML).21PubMed. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned PML destroys brain tissue aggressively and can be fatal or leave severe permanent disability.
The risk is highest in people who test positive for JC virus antibodies, have been on the drug for more than two years, and have previously used other immunosuppressants. Since the initial cases were identified, neurologists have developed screening protocols using blood tests for JC virus antibodies to stratify risk before and during treatment.22JAMA Neurology. Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions Other MS drugs, including some newer oral therapies and other monoclonal antibodies, can also suppress immune function enough to increase the risk of serious infections, though PML specifically remains most closely associated with natalizumab. For most people, the benefits of disease-modifying therapy far outweigh the risks, but the risk-benefit conversation is real and ongoing.
The Role of Comorbidities
MS does not exist in isolation. People with the disease also develop diabetes, heart disease, lung disease, and other chronic conditions at rates similar to or higher than the general population, and these comorbidities interact with MS in dangerous ways. A Canadian study found that diabetes, ischemic heart disease, depression, anxiety, and chronic lung disease were all independently associated with a higher risk of death in people with MS.23PubMed Central. Effect of comorbidity on mortality in multiple sclerosis The two most common categories of causes of death in the MS population were diseases of the nervous system and diseases of the circulatory system.23PubMed Central. Effect of comorbidity on mortality in multiple sclerosis
Managing these conditions can be harder when you have MS. Exercise is more difficult with mobility limitations. Depression saps motivation to manage diet and medications. Cognitive problems from MS can make it harder to keep track of complex medication regimens. The result is that a comorbidity that would be well-controlled in someone without MS can spiral in someone who has it.
Malnutrition in Advanced Disease
As MS progresses, the combination of swallowing difficulty, fatigue, reduced mobility, and sometimes cognitive decline can lead to malnutrition and eventually cachexia, a wasting syndrome where the body breaks down its own muscle. This is not simply “not eating enough.” It is a metabolic collapse that weakens the immune system, accelerates muscle loss in the limbs, and further impairs the respiratory muscles, creating a vicious cycle where the ability to fight off infections deteriorates just as the risk of acquiring them peaks.24PubMed Central. Nutritional status of multiple sclerosis (MS) patients attending Kasr Alainy MS unit: an exploratory cross-sectional study By this stage, infections from any source, whether a UTI, a pressure sore, or aspiration, are far more likely to overwhelm the body’s defenses.
Why the Cause of Death Often Looks Unrelated to MS
One reason MS mortality is poorly understood by the general public is that the death certificate often lists something like “pneumonia” or “sepsis” or “pulmonary embolism” rather than MS itself. When researchers looked at U.S. death certificates and compared those that mentioned MS to matched deaths that did not, the differences were stark across infection categories and skin disease.6PubMed Central. Multiple cause of death analysis in multiple sclerosis: A population-based study MS was the predisposing condition, but the proximate killer was something else. This means that studies relying only on the “underlying cause of death” field on certificates undercount the true toll of MS. It also means that families sometimes hear a cause of death that sounds unconnected to the disease their loved one had been fighting for decades, which can be confusing and isolating.
For people living with MS, the practical implication is that prevention of these downstream complications matters enormously. Regular swallowing assessments, aggressive treatment of UTIs, skin checks and repositioning schedules, compression stockings or anticoagulants for clot prevention, pulmonary function monitoring, depression screening, and nutritional support are all interventions that target the actual mechanisms by which MS shortens life. None of them sound like MS treatment, and that is exactly the point. The disease creates the vulnerability; proactive management of the vulnerabilities is what keeps people alive longer.